Category: Achondroplasia

BioMarin Pharma sees big things for first FDA-approved dwarfism drug

November 21, 2021 Auto Bot 0

BioMarin Pharmaceutical’s Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in […]

BioMarin Report Results of Vosoritide in P-III OLE Study for the Treatment of Children with Achondroplasia at ENDO 2021

March 22, 2021 Auto Bot 0

Shots: The ongoing P-III OLE study involves assessing Vosoritide (15 mcg/kg) vs PBO in 119 children with achondroplasia. The CHMP opinion is expected in Europe […]

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

August 21, 2020 Auto Bot 0

Shots: BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia The company also reported that EMA has begun […]

BioMarin Reports the Submission of MAA to EMA for Vosoritide to Treat Children with Achondroplasia

July 24, 2020 Auto Bot 0

Shots: The MAA is based on P-III study assessing the efficacy and safety of vosoritide, further supported by the long-term safety and efficacy from the […]